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Permanent neonatal diabetes mellitus is a rare disorder known to be caused
by activating mutations in KCNJ11 or ABCC8, inactivating mutations in
INS, or very rarely in GCK or insulin promotor factor-1 (IPF-1) genes. We
report a patient with permanent neonatal diabetes mellitus and severe
exocrine pancreatic insufficiency. Ultrasound examination revealed
pancreatic agenesis with a suggestion of a small amount of tissue in the head
of the pancreas. Genetic testing revealed that the neonate had a
homozygous Pro63fsX60 IPF-1 mutation. This is the second reported case
of neonatal diabetes mellitus secondary to a homozygous mutation in the
IPF-1 gene and supports the previously proposed biological role of IPF-1 in
the pancreatic development in human.
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Neonatal diabetes mellitus is a rare disease with an
estimated incidence of 1 in 450 000 (1). It is defined as
insulin-requiring hyperglycemia occurring within the
first few months of life and lasting more than 2 wk (2).
The cases appear to be almost evenly divided between
permanent and transient neonatal diabetes with similar
presentations of growth retardation, dehydration, and
hyperglycemia. Although transient neonatal diabetes
usually resolves within 6 months to 1 yr with potential
recurrence of diabetes during childhood or adolescence,
permanent neonatal diabetes does not resolve or remit
(2). Permanent neonatal diabetes can have different
etiologies, which can include abnormalities in the genes
coding for pancreatic β-cell ATP-sensitive potassium
channels, enzymes such as glucokinase or the proteins
involved in the development of the pancreas (3–5).
In 1993, a neonate was described with permanent
neonatal diabetes and exocrine pancreatic insufficiency
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because of congenital pancreatic agenesis (6) who
in 1997 was then found to harbor a homozygous
insulin promotor factor-1 (IPF-1) gene mutation (4). A
second infant was described with pancreatic agenesis,
neonatal diabetes, and pancreatic insufficiency because
of a compound heterozygous mutation of the IPF-
1 gene (7). We are now presenting a third neonate
with permanent neonatal diabetes and severe exocrine
pancreatic insufficiency because of an IPF-1 gene
mutation and the second case with a homozygous
IPF-1 mutation, who on ultrasound examination has
pancreatic agenesis and a suggestion of a small amount
of tissue in the head of the pancreas.
Case report
The propositus, a male infant with a birth weight of
1.56 kg, was born at 37 wk gestation to a 21-yr-old,
Caucasian G2P1 mother. Pregnancy was complicated
by gestational diabetes that was treated with insulin. At
37 wk, he was delivered by caesarean section because of
oligohydramnios and intra-uterine growth retardation.
APGAR scores were 8 at 1 min and 9 at 5 min. Because
he was an infant of a mother who had gestational
diabetes, blood glucoses were monitored carefully. His
initial blood glucose was 110 mg/dL (6.05 mmol/L).
Within 24 h of life, his blood glucose was as high as
378 mg/dL (20.79 mmol/L). A sepsis evaluation was
initiated, which was eventually reported as negative.
He was started on an intravenous insulin drip and
received between 1/2 to 1 unit of regular insulin a day.
Urine ketones were negative. However, he was prone to
quick changes in blood glucose and experienced hypo-
glycemia with small changes in the insulin dosage. At
8 d of life, when it was evident that the hyperglycemia
was not a transient problem, he was transferred to our
facility.
On arrival to our Neonatal Intensive Care Unit,
the following measures were recorded when blood
glucose was 346 mg/dL (19.03 mmol/L): GAD-65
and insulin autoantibodies were negative, C-peptide
<0.5 ng/mL (<0.166 nmol/L) with a reference range
of 1–5.2 ng/mL (0.33–1.72 nmol/L) and insulin
< 2μU/mL (<0.08μg/L) with a normal range of
5–15μU/mL (0.2–0.62μg/L). Physical examination
was unremarkable and did not reveal dysmorphic
features or physical abnormalities. He was continued
on the insulin drip and fed continuously with
Neosure 22 kcal/oz. Target blood glucose was set at
120–300 mg/dL (6.6–16.5 mmol/L).
Within 3 wk of birth, despite significant intake
of formula, he had persistent weight loss and foul-
smelling stools. Reducing substances were present in the
stool. Stool elastase levels were<50μg elastase/g stool,
indicating severe exocrine pancreatic insufficiency and
treatment was initiated with pancreatic enzymes.
He was eventually transitioned to bolus feeding.
Initially, diluted neutral protamine Hagedorn (NPH)
and Glargine were given. Diluted regular insulin and
Glargine were then tried. Finally, the Lilly diluent was
acquired enabling the use of prediluted regular insulin
that was diluted from the U-100 vial (100 units/mL)
once every 2 wk. However, Glargine still had to be
diluted immediately before administration.
Because of the difficulty of giving small amounts of
diluted insulin and difficulty of maintaining his blood
glucose without wide fluctuations, it was decided that
the baby would benefit from a continuous subcutaneous
insulin infusion (CSII) regimen using diluted insulin.
Diluted Lispro (U-10, 10 units/mL) was administered
via an Animas pump. This pump was chosen because
it could deliver the smallest basal and boluses possible
among all the commercially available insulin pumps.
Soon after, the baby’s blood glucose levels did improve
into the 200–300 mg/dL (11–16.5 mmol/L) range, with
very few hypoglycemic events. Insulin to carbohydrate
coverage charts and correction charts for high blood
glucoses were given to the family for them to calculate
the amount of insulin based on volume of formula and
blood glucose measurements done approximately every
3 h. A low basal rate was calculated to protect him
from significant hypoglycemia in case of inadequate
oral intake.
His first hemoglobin A1c (HbA1c; done by Bayer
DCA 2000+ HbA1c analyzer, Bayer HealthCare LLC,
Tarrytown, NY, USA) at 2 months was 7.2%, but the
reliability of the measurement was uncertain because
of the fetal hemoglobin expected to be present based
on his age (8). His 3-month HbA1c (Bayer DCA
2000+) was 9%. His HbA1c [done by high performance
liquid chromatography (HPLC)] at 4 months of age
was 12.1%. The amount of fetal hemoglobin present
was then calculated to be approximately 8–10%. His
HbA1c (Bayer DCA 2000+) at 17 months of age was
9%. He was receiving approximately 0.8 units/kg/d
of Lispro insulin via CSII. This insulin requirement
is approximately 75th percentile for a 2-yr-old child
with type 1 diabetes (9). It has been difficult to
manage this infant because of wide fluctuations in
blood glucose concentrations from 50 to 400 mg/dL
(2.75–22 mmol/L) in quick succession, inconsistency
of appetite and feeding schedule, malabsorption,
subcutaneous infections at the pump site insertion, and
frequent illnesses. This experience appears to be similar
to others who have also managed infants with neonatal
diabetes (10, 11). We have recently discontinued CSII
therapy at his mother’s request. On basal bolus therapy
with Glargine and diluted Lispro, his blood glucose
concentrations now range between 100 and 250 mg/dL
(5.5–11 mmol/L). His growth was poor initially, but
once he was started on insulin and a pancreatic enzyme
replacement, he has demonstrated steady weight gain.
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However, he has not yet experienced catch-up growth
(growth chart is included in Fig. 1).
The initial ultrasound (at 2 wk of age) of his pancreas
visualized portions of the mid and distal body of the
pancreas that appeared structurally normal. No focal
mass was identified. A subsequent ultrasound 1 wk
later was interpreted as showing the presence of only
the head of the pancreas. A computed tomography
(CT) of the pancreas without sedation at 7 months
of age showed a small amount of tissue anterior to
the splenic vein that could either represent pancreas
or small bowel. Ultrasound examination at 1 yr of
age revealed a small hypoechoic structure in the area
of the pancreatic head, but because of his small size
a definitive conclusion was not rendered. A magnetic
resonance imaging (MRI) at 5 yr of age was suggested
for confirmation.
Family history is notable as his mother had
gestational diabetes with both of her pregnancies, which
were treated with insulin. The father, who is 22-yr
old, has had hyperglycemia by home blood glucose
monitoring since age 15 yr and is now treated with oral
agents. Both maternal and paternal grandparents are












































































































































Fig. 1. Our propositus’s height and weight growth charts.
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parents were later determined to have maturity-onset
diabetes of the young (MODY) (SS Fajans, GI Bell,
VP Paz et al., manuscript in preparation).
Microsatellite analysis of chromosome 6 for uni-
parental inheritance, which has been described in
transient neonatal diabetes, was reported as normal.
Diagnostic genetic testing for permanent neonatal dia-
betes carried out by Athena Diagnostics (Worchester,
MA, USA) revealed a homozygous mutation in the
IPF-1 gene (nucleotide change of c.188delC with a
predicted amino acid change of p.Pro63fsX60) with
normal sequences in KCNJ11 and GCK genes. Our
patient was also tested for mutations in the cystic
fibrosis gene because he exhibited clinical evidence of
malabsorption as a result of exocrine pancreatic insuf-
ficiency. Interestingly, he was found to be a carrier of
the mutated CFTR gene (4006-46delTATTT).
Discussion
In our infant, the combination of severe exocrine
pancreatic insufficiency and permanent neonatal
diabetes suggested the possibility of pancreatic agenesis
and by association the presence of an IPF-1 mutation.
Indeed, our patient was found to have a homozygous
IPF-1 mutation Pro63fsX60. The same homozygous
Pro63fsdelC mutation was present in the first infant
with IPF-1 mutation previously described (4). This
suggests, but does not prove, that the families of the
two probands may be related. Homozygosity implies
that consanguinity may have existed in the parents’
families, as was reported in the previous family (4).
There are other causes for permanent neonatal
diabetes. Heterozygous activating mutations in the
KCNJ11 gene, which encodes the Kir6.2 subunit of the
KATP channel, are thought to be the most common
cause of permanent neonatal diabetes (3, 12). In a
recent study by Edghill et al., KCNJ11 mutations were
found in 31% of individuals with neonatal diabetes
(12). Mutations in the ABCC8 and insulin gene were,
respectively, found in 10 and 12% of the individuals
(12). With these causes, exocrine pancreatic function
is preserved.
Baumeister et al. compiled 14 cases of pancreatic
agenesis associated with neonatal diabetes (13). Many
of these neonates had associated malformations such
as biliary system or heart abnormalities that increased
their morbidity (13). Several other studies have also
noted that pancreatic hypoplasia can be associated with
congenital heart disease (14), intestinal atresia, and
gall bladder hypoplasia (15). Another possibility was
the X-linked IPEX syndrome (immunodysregulation,
polyendocrinopathy, and enteropathy) secondary to a
mutation in the FOXP3 gene (16). However, because
our proband did not develop any further endocrine
abnormalities, this possibility was not pursued.
Our patient may have a small portion of the head of
the pancreas as suggested by ultrasound examination
at 12 months of age. Multiple transcription factors are
involved in the development, maintenance and function
of the pancreas (17). Our patient has a homozygous
mutation in the IPF-1 gene, also known as Pancreas
Duodenum Homeobox-1 (PDX-1). IPF-1 is a tran-
scription factor necessary for development and growth
of the pancreas (18), but may not be involved in the
primary initiation of pancreatic development (17). In
mice, IPF-1 expression can be first identified while the
exocrine pancreas is forming embryonically (18). In the
pancreatic endoderm of Pdx1−/− mice, small rudimen-
tary buds with glucagon+ cells have been detected (17,
19), but further growth of the pancreas did not occur,
which suggested that PDX1/IPF-1 may be necessary
for sustained differentiation for both the endocrine and
exocrine components of the pancreas (17).
A heterozygous IPF-1 mutation results in a MODY4
phenotype. Homozygous mutations lead to neonatal
diabetes, which has been attributed to pancreatic
agenesis. Both parents carry the heterozygous mutation
in IPF-1 gene (SS Fajans, GI Bell, VP Paz et al., in
prep.). To date, there has been only one other case
with the same homozygous mutation as our proband
(4). That child presented at 18 d of life and was
confirmed by ultrasound in the neonatal period to have
pancreatic agenesis (4). Another female who developed
hyperglycemia at 12 d of life was found to have a
compound heterozygous mutation of the IPF-1 gene
that also resulted in pancreatic agenesis (7). Marsh’s
group reported on four more children with neonatal
diabetes and pancreatic agenesis or hypoplasia (20).
Several genes that code for transcription factors other
than IPF-1 (Ptf1a, Sox9, Sox17, Hnf6, H1xB9) were
screened. None carried an IPF-1 mutation, but new
polymorphisms were found that were not thought to
be disease-causing because similar changes were also
found in unaffected individuals (20).
In summary, we report what we believe to be the
second case of neonatal diabetes, exocrine pancreatic
insufficiency, and pancreatic agenesis caused by a
homozygous IPF-1 mutation. In mice, IPF-1 is known
to be involved in the continuing development and
maintenance of the pancreas but not in its induction.
The possible presence of a small amount of tissue in
the head of the pancreas on ultrasound examination
could provide clues as to biological role of IPF-1 in the
pancreatic development in humans.
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